5 French stocks that may have been penalized too harshly according to Barclays By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2024
0mins
Should l Buy SNY?
Source: Investing.com
- French Stocks Rebound: French stocks bounced back after significant losses last week, with the CAC 40 closing up 0.91% on Monday.
- Buying Opportunities: Barclays analysts suggest that the current situation could present buying opportunities for investors.
- Uncertain Legislative Elections: Polls indicate uncertain outcomes for legislative elections, leading to erratic price movements in the stock market.
- Main Risks for Investors: Barclays highlighted main risks concerning investors amid the current political uncertainty.
- Stock Recommendations: Barclays provided ratings and price targets for various stocks, including BNP Paribas, Edenred, Veolia Environnement SA ADR, Vinci SA, and Sanofi. They also mentioned telecom operators Orange SA ADR and Bouygues as more vulnerable due to exposure to the French domestic market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNY
Wall Street analysts forecast SNY stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 45.140
Low
57.00
Averages
79.36
High
119.07
Current: 45.140
Low
57.00
Averages
79.36
High
119.07
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- First Targeted Therapy: Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for moderate-to-severe bullous pemphigoid, marking it as the first targeted therapy for this rare skin disease, significantly improving patients' quality of life.
- Clinical Trial Support: Data from the LIBERTY-BP-ADEPT Phase 2/3 trial showed that patients treated with Dupixent were over four times more likely to achieve sustained disease remission compared to placebo, indicating its substantial efficacy.
- Reduced Steroid Dependence: Dupixent allows patients to taper off steroids earlier, reducing reliance on immunosuppressive therapy, which enhances both safety and effectiveness of the treatment.
- Sales Growth Potential: Dupixent is projected to generate €15.7 billion in global sales by 2025, a 25% increase from €13.1 billion in 2024, highlighting its strong potential as a key growth driver for Sanofi.
See More
Senate Reaches Bipartisan Deal to Cap Insulin Costs at $35
- Insulin Cost Cap: A bipartisan group of senators has reached an agreement to cap insulin costs at $35 per month for individuals with employer or state marketplace insurance, aiming to enhance drug affordability and alleviate financial burdens for millions of Americans.
- Benefits for Uninsured: The legislation includes a pilot program in 10 states allowing uninsured individuals to purchase insulin at the lower price, which will expand access to essential medication and support more diabetes patients in receiving necessary treatment.
- Bill Introduction and Support: Titled the 'Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026,' the bill is introduced by Senator Jeanne Shaheen and three other senators, reflecting bipartisan cooperation, although it still requires convincing Senate Majority Leader to gain traction.
- Policy Impact and Outlook: If passed, this legislation will address the growing affordability crisis surrounding insulin in the U.S., and if signed by President Trump, it will represent a significant advancement in healthcare policy, impacting a broad patient demographic.
See More
U.S. Senators Reach Agreement to Cap Insulin Prices
- Insulin Price Cap: A bipartisan group of U.S. senators has reached an agreement to cap insulin prices at $35 per month, aiming to alleviate the financial burden for nearly 30 million Americans diagnosed with diabetes, highlighting a commitment to improving public health.
- Legislative Progress: The proposal, led by Jeanne Shaheen and Susan Collins, requires support from Senate Majority Leader John Thune and President Trump, indicating the political significance and urgency of the bill in addressing healthcare costs.
- Expanded Coverage: Initially focused on insured patients, the bill now includes a pilot program allowing uninsured individuals in 10 states to access insulin at capped prices, reflecting a commitment to supporting vulnerable populations.
- Positive Market Reaction: Following the announcement, shares of major insulin producers rose in pre-market trading, with Sanofi up 2% and Eli Lilly and Novo Nordisk each gaining around 0.5%, indicating market optimism regarding the potential impact of the legislation.
See More
Bipartisan Agreement Among US Senators Aims to Limit Insulin Prices to $35 – SNY, LLY, NVO Stocks Rise in Pre-Market Trading
Proposed Legislation: A bipartisan group of U.S. senators has proposed a plan to cap insulin prices at $35 to alleviate financial burdens for millions living with diabetes, requiring support from Senate Majority Leader John Thune and President Donald Trump.
Inclusion of Uninsured Patients: The initial focus of the proposal was on insured patients, but senators John Kennedy and Raphael Warnock advocated for including uninsured individuals in the plan.
Pilot Program: The bill suggests a pilot program in 10 states to allow uninsured patients access to insulin at capped prices, addressing the high costs associated with diabetes treatment.
Pharmaceutical Cost Reforms: The legislation also aims to reduce costs by reforming pharmacy benefit manager rebate systems, although specific funding details are still being finalized.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- New Indication Approval: The Ministry of Health, Labour and Welfare in Japan has approved Dupixent (dupilumab) for the treatment of moderate-to-severe bullous pemphigoid, marking the seventh approved indication for the drug in Japan and reinforcing its market position in dermatology.
- Clinical Trial Support: This approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial, demonstrating Dupixent's efficacy in improving patient symptoms, providing a strong scientific basis for its promotion in Japan.
- Market Reaction: Following this announcement, Sanofi's shares fell by 1.23% to €76.83, reflecting market caution regarding the new drug approval, which may impact short-term shareholder confidence.
- Strategic Implications: The multiple indications for Dupixent not only enhance Sanofi's competitiveness in immunotherapy but also have the potential to drive sales growth in the Japanese market, further expanding the company's influence in the global biopharmaceutical landscape.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Clinical Trial Results: Dupixent (dupilumab) has been approved in Japan for the treatment of moderate-to-severe bullous pemphigoid (BP), based on the LIBERTY-BP-ADEPT Phase 2/3 trial results, which showed that 18% of Dupixent patients achieved sustained disease remission at Week 36, significantly higher than the 4% in the placebo group (p=0.0250), indicating its potential to improve patient quality of life.
- Safety Analysis: In the Dupixent group, 26% of patients experienced treatment-related adverse events (AEs), compared to 15% in the placebo group, with conjunctivitis being the most common AE at 4%, highlighting the need for careful safety management in clinical applications.
- Market Expansion: This approval marks the seventh indication for Dupixent in Japan, where it is also approved for atopic dermatitis, asthma, and other conditions, demonstrating its broad market applicability and further solidifying Regeneron and Sanofi's leadership in the immunotherapy space.
- Innovative Treatment Regimen: Dupixent is administered via subcutaneous injection every two weeks, in conjunction with standard oral corticosteroid (OCS) therapy, effectively controlling BP symptoms, which is expected to provide patients with more flexible treatment options, enhancing adherence and therapeutic outcomes.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- First Targeted Therapy: Japan's Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for moderate-to-severe bullous pemphigoid, marking it as the first targeted therapy for this rare skin disease, significantly improving patients' quality of life.
- Clinical Trial Support: Data from the LIBERTY-BP-ADEPT Phase 2/3 trial showed that patients treated with Dupixent were over four times more likely to achieve sustained disease remission compared to placebo, indicating its substantial efficacy.
- Reduced Steroid Dependence: Dupixent allows patients to taper off steroids earlier, reducing reliance on immunosuppressive therapy, which enhances both safety and effectiveness of the treatment.
- Sales Growth Potential: Dupixent is projected to generate €15.7 billion in global sales by 2025, a 25% increase from €13.1 billion in 2024, highlighting its strong potential as a key growth driver for Sanofi.
See More
Senate Reaches Bipartisan Deal to Cap Insulin Costs at $35
- Insulin Cost Cap: A bipartisan group of senators has reached an agreement to cap insulin costs at $35 per month for individuals with employer or state marketplace insurance, aiming to enhance drug affordability and alleviate financial burdens for millions of Americans.
- Benefits for Uninsured: The legislation includes a pilot program in 10 states allowing uninsured individuals to purchase insulin at the lower price, which will expand access to essential medication and support more diabetes patients in receiving necessary treatment.
- Bill Introduction and Support: Titled the 'Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026,' the bill is introduced by Senator Jeanne Shaheen and three other senators, reflecting bipartisan cooperation, although it still requires convincing Senate Majority Leader to gain traction.
- Policy Impact and Outlook: If passed, this legislation will address the growing affordability crisis surrounding insulin in the U.S., and if signed by President Trump, it will represent a significant advancement in healthcare policy, impacting a broad patient demographic.
See More
U.S. Senators Reach Agreement to Cap Insulin Prices
- Insulin Price Cap: A bipartisan group of U.S. senators has reached an agreement to cap insulin prices at $35 per month, aiming to alleviate the financial burden for nearly 30 million Americans diagnosed with diabetes, highlighting a commitment to improving public health.
- Legislative Progress: The proposal, led by Jeanne Shaheen and Susan Collins, requires support from Senate Majority Leader John Thune and President Trump, indicating the political significance and urgency of the bill in addressing healthcare costs.
- Expanded Coverage: Initially focused on insured patients, the bill now includes a pilot program allowing uninsured individuals in 10 states to access insulin at capped prices, reflecting a commitment to supporting vulnerable populations.
- Positive Market Reaction: Following the announcement, shares of major insulin producers rose in pre-market trading, with Sanofi up 2% and Eli Lilly and Novo Nordisk each gaining around 0.5%, indicating market optimism regarding the potential impact of the legislation.
See More
Bipartisan Agreement Among US Senators Aims to Limit Insulin Prices to $35 – SNY, LLY, NVO Stocks Rise in Pre-Market Trading
Proposed Legislation: A bipartisan group of U.S. senators has proposed a plan to cap insulin prices at $35 to alleviate financial burdens for millions living with diabetes, requiring support from Senate Majority Leader John Thune and President Donald Trump.
Inclusion of Uninsured Patients: The initial focus of the proposal was on insured patients, but senators John Kennedy and Raphael Warnock advocated for including uninsured individuals in the plan.
Pilot Program: The bill suggests a pilot program in 10 states to allow uninsured patients access to insulin at capped prices, addressing the high costs associated with diabetes treatment.
Pharmaceutical Cost Reforms: The legislation also aims to reduce costs by reforming pharmacy benefit manager rebate systems, although specific funding details are still being finalized.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- New Indication Approval: The Ministry of Health, Labour and Welfare in Japan has approved Dupixent (dupilumab) for the treatment of moderate-to-severe bullous pemphigoid, marking the seventh approved indication for the drug in Japan and reinforcing its market position in dermatology.
- Clinical Trial Support: This approval is based on data from the LIBERTY-BP-ADEPT Phase 2/3 trial, demonstrating Dupixent's efficacy in improving patient symptoms, providing a strong scientific basis for its promotion in Japan.
- Market Reaction: Following this announcement, Sanofi's shares fell by 1.23% to €76.83, reflecting market caution regarding the new drug approval, which may impact short-term shareholder confidence.
- Strategic Implications: The multiple indications for Dupixent not only enhance Sanofi's competitiveness in immunotherapy but also have the potential to drive sales growth in the Japanese market, further expanding the company's influence in the global biopharmaceutical landscape.
See More
Dupixent Approved in Japan for Bullous Pemphigoid Treatment
- Clinical Trial Results: Dupixent (dupilumab) has been approved in Japan for the treatment of moderate-to-severe bullous pemphigoid (BP), based on the LIBERTY-BP-ADEPT Phase 2/3 trial results, which showed that 18% of Dupixent patients achieved sustained disease remission at Week 36, significantly higher than the 4% in the placebo group (p=0.0250), indicating its potential to improve patient quality of life.
- Safety Analysis: In the Dupixent group, 26% of patients experienced treatment-related adverse events (AEs), compared to 15% in the placebo group, with conjunctivitis being the most common AE at 4%, highlighting the need for careful safety management in clinical applications.
- Market Expansion: This approval marks the seventh indication for Dupixent in Japan, where it is also approved for atopic dermatitis, asthma, and other conditions, demonstrating its broad market applicability and further solidifying Regeneron and Sanofi's leadership in the immunotherapy space.
- Innovative Treatment Regimen: Dupixent is administered via subcutaneous injection every two weeks, in conjunction with standard oral corticosteroid (OCS) therapy, effectively controlling BP symptoms, which is expected to provide patients with more flexible treatment options, enhancing adherence and therapeutic outcomes.
See More
